Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeyondSpringBYSI +0.81%25 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus rates BYSI with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 153 Biotechnology companies, BeyondSpring ranks worse than 653594.12% on this metric.
BeyondSpring's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for BeyondSpring's 5-Year Yield-on-Cost % or its related term are showing as below:
BYSI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.73 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
BeyondSpring 5-Year Yield-on-Cost % Related Terms
BYSI vs PLRX, MCRB, XBIT: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, BeyondSpring's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeyondSpring 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeyondSpring's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where BeyondSpring's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of BeyondSpring is calculated as
BeyondSpring (BYSI) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BeyondSpring and its competitors. According to the industry distribution chart, BeyondSpring ranks #999999 out of 153 companies in the Biotechnology industry.
Is BeyondSpring's 5-Year Yield-on-Cost % too high?
BeyondSpring's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, BeyondSpring ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeyondSpring has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does BeyondSpring's 5-Year Yield-on-Cost % compare to PLRX and MCRB?
According to the Biotechnology industry distribution chart, BeyondSpring ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places BeyondSpring in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.73, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BeyondSpring and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeyondSpring's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeyondSpring stock overvalued right now?
BeyondSpring (BYSI) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. BeyondSpring's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For BeyondSpring (BYSI), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
25GF Score
Get the complete analysis for BYSI
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BYSI has been successfully added to your 
